Breaking News

Tweet TWEET

MorphoSys Rises on $818 Million Drug Alliance: Frankfurt Mover

MorphoSys AG (MOR) rose to a 12-year high after announcing an alliance for an experimental cancer treatment with Celgene Corp. (CELG) worth as much as 628 million euros ($818 million) plus royalties on sales.

The stock jumped 17 percent to 43.50 euros as of 9:42 a.m. in Frankfurt, the highest price since February 2001. That gave the Martinsried, Germany-based company a value of about 1 billion euros. The shares have gained 48 percent this year.

The companies said they will co-develop and co-promote MorphoSys’s MOR202 drug for diseases including multiple myeloma, a type of blood cancer. The deal comes with an upfront payment of 70.8 million euros, and MorphoSys will also receive 46.2 million euros from Summit, New Jersey-based Celgene for new shares of MorphoSys. The German drugmaker is also entitled to payments upon meeting development, regulatory and sales goals as well as a double-digit cut of sales.

“This alliance takes MorphoSys to the next stage of our corporate development,” Chief Executive Officer Simon Moroney said in the statement.

This is MorphoSys’s second transaction this month. The company said June 3 it agreed to sell rights to its experimental MOR103 treatment to GlaxoSmithKline Plc (GSK) for as much as 445 million euros as well as royalties.

MorphoSys spokeswoman Claudia Gutjahr-Loeser said the company will adjust its financial guidance after it receives U.S. antitrust clearance for the deal. The company raised its forecast for earnings before interest and tax after the GlaxoSmithKline agreement to a range from a loss of 2 million euros to earnings of 2 million euros.

Previously the forecast was for a loss at that level of 18 million euros to 22 million euros.

To contact the reporter on this story: Eva von Schaper in Munich at evonschaper@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.